نتایج جستجو برای: tb vaccine

تعداد نتایج: 133682  

Journal: :Journal of infection in developing countries 2009
Giovanni Delogu Giovanni Fadda

Tuberculosis (TB) is still one of the deadliest human diseases, killing 1,6 million people each year, mostly in developing countries. The vaccine currently used, Bacille Calmette and Guerin (BCG), is effective in preventing the most severe disseminated forms of disease in children and newborns, but its efficacy against active TB in adults has been challenged by several clinical studies. It is a...

Journal: :vaccine research 0
ar hadizadeh tasbiti sh yari m ghanei sd siadat s niknami a bahrmand

introduction: infections by multidrug resistant mycobacterium tuberculosis (mdr-tb) is a major public health challenge. secretion of proteins by m. tuberculosis plays an important role in the pathogenesis of the bacterium. we compared the protein profiles of susceptible m. tuberculosis and mdr-tb isolates using proteomic analyses, namely two dimensional gel electrophoresis (2de) and mass spectr...

2017
Natalie E. Nieuwenhuizen Prasad S. Kulkarni Umesh Shaligram Mark F. Cotton Cyrill A. Rentsch Bernd Eisele Leander Grode Stefan H. E. Kaufmann

The only licensed vaccine against tuberculosis (TB), bacille Calmette-Guérin (BCG), protects against severe extrapulmonary forms of TB but is virtually ineffective against the most prevalent form of the disease, pulmonary TB. BCG was genetically modified at the Max Planck Institute for Infection Biology to improve its immunogenicity by replacing the urease C encoding gene with the listeriolysin...

2017
E. W. Bunyasi A. K. K. Luabeya M. Tameris H. Geldenhuys H. Mulenga B. S. Landry T. J. Scriba B-M. Schmidt W. A. Hanekom H. Mahomed H. McShane M. Hatherill

SETTING South Africa. OBJECTIVE To evaluate the long-term effectiveness of infant modified vaccinia Ankara virus-expressing antigen 85A (MVA85A) vaccination against tuberculosis (TB). DESIGN We analysed data from a double-blind randomised placebo-controlled Phase 2b MVA85A infant TB vaccine trial (2009-2012), with extended post-trial follow-up (2012-2014). Isoniazid preventive therapy (IPT)...

Journal: :Infection and immunity 2013
Rajko Reljic Laura Sibley Jen-Min Huang Ilaria Pepponi Andreas Hoppe Huynh A Hong Simon M Cutting

Needle-free, mucosal immunization is a highly desirable strategy for vaccination against many pathogens, especially those entering through the respiratory mucosa, such as Mycobacterium tuberculosis. Unfortunately, mucosal vaccination against tuberculosis (TB) is impeded by a lack of suitable adjuvants and/or delivery platforms that could induce a protective immune response in humans. Here, we r...

2015
Vishwanath Venketaraman Deepak Kaushal Beatrice Saviola

Copyright © 2015 Vishwanath Venketaraman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Mycobacterium tuberculosis (M. tuberculosis), the causative agent for tuberculosis (TB), is responsible for 1.5 million deaths and 9 m...

Journal: :Pathogens and disease 2014
Esaki M Shankar Ramachandran Vignesh Rada Ellegård Muttiah Barathan Yee K Chong M Kahar Bador Devi V Rukumani Negar S Sabet Adeeba Kamarulzaman Vijayakumar Velu Marie Larsson

Tuberculosis (TB) and human immunodeficiency virus (HIV) infection interfere and impact the pathogenesis phenomena of each other. Owing to atypical clinical presentations and diagnostic complications, HIV/TB co-infection continues to be a menace for healthcare providers. Although the increased access to highly active antiretroviral therapy (HAART) has led to a reduction in HIV-associated opport...

Journal: :Thorax 2014
S W Michelsen B Soborg A Koch L Carstensen S T Hoff E M Agger T Lillebaek H C F Sorensen J Wohlfahrt M Melbye

BACKGROUND The BCG vaccine's ability to prevent Mycobacterium tuberculosis infection (MTI) remains highly debated. In Greenland, BCG vaccination was introduced in 1955, but was temporarily discontinued (1991-1996) due to nationwide policy changes. The study aimed to use the transient stop in BCG vaccination to evaluate the effect of vaccination on MTI prevalence and TB incidence. METHODS MTI ...

Journal: :Bulletin of the World Health Organization 2002
Ann M Ginsberg

Over the past 10 years, tuberculosis (TB) vaccine development has resurged as an active area of investigation. The renewed interest has been stimulated by the recognition that, although BCG is delivered to approximately 90% of all neonates globally through the Expanded Programme on Immunization, Mycobacterium tuberculosis continues to cause over 8 million new cases of TB and over 2 million deat...

Journal: :American journal of respiratory and critical care medicine 2012
Thomas J Scriba Michele Tameris Erica Smit Linda van der Merwe E Jane Hughes Blessing Kadira Katya Mauff Sizulu Moyo Nathaniel Brittain Alison Lawrie Humphrey Mulenga Marwou de Kock Lebohang Makhethe Esme Janse van Rensburg Sebastian Gelderbloem Ashley Veldsman Mark Hatherill Hendrik Geldenhuys Adrian V S Hill Anthony Hawkridge Gregory D Hussey Willem A Hanekom Helen McShane Hassan Mahomed

RATIONALE Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control. OBJECTIVE To determine the safety and immunogenicity of MVA85A, a novel TB vaccine, among M.tb- and/or HIV-infected persons in a setting where TB and HIV are endemic. METHODS An open-label, phase IIa trial was conducted i...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید